Mater's Thesis PowerPoint resume. · Alzheimer's Disease · Alzheimer's management · Alzheimer's healthcare Contact me via LinkedIn: www.linkedin.com/in/marcosdiazalzheimerresearch

1. Toward to a pre-symptomatic diagnosis ofToward to a pre-symptomatic diagnosis of
Alzheimer’sAlzheimer’s
Marcos Díaz Díaz
Salamanca 2013

2. Index
 Alzheimer’s Disease
 Epidemiology and costs
 Limitations of diagnosis criteria
 Neuroimaging
 Biomarkers
 Current treatment for AE
 Redefinition of disease

3. Alheimer’s Disease
 Neurodegenerative disease
 Unknown etiology
 Etiopathogenic puzzle
 Neurofibrillary tangles
 Neuritic plaques (APP)
 “Amyloid cascade”
 ApoE

4. Epidemiology & costs
 2010: more than half a million in Spain
 2050: 1.5 million in Spain
 2050: 115 million in the world
 WHO: 215 thousand million €/year in dementia
 Spain: 24.000€ / Europe: 54.000€
 286h/month – 70h/week
 Studies-researches:
 Winsconsin
 United Biosource

5. Limitations of diagnosis criteria
 Screening tests in primary attention
 DSM-IV
 CIE-10
 Mild cognitive impairment –MCI-
 Cognitive reserve theory
Too late

6. Neuroimaging
 Computerized Tomography (CT)
 Magnetic Resonance Imaging (MRI)
 Single-Photon Emission Computed Tomography (SPECT)
 Positron Emission Tomography (PET)
 FDG
 FDDNP
 PIB
 F-BAY94-9172
 Florbetapir-F-18

7. Biomarkers
 Genetic biomarkers
 CSF biomarkers
 β-amiloide peptide
 Tau protein
 T-tau
 P-tau
 β-amiloide & tau proteins combined
 β-amiloide & tau proteins in MCI
 Concomitant use of different biomarkers

8. Biomarkers

9. Current treatment for AE
 Non-pharmacological therapy & concomitant therapy
 AchE-Inhibitors & memantine
 Monoclonal antibody (mab)
 Bapineuzumab
 Scarlet Road Study
 Gantenerumab
 Washington University Study
 Gantenerumab
 Solanezumab
 LY2886721

10. Redefinition of disease
 Clinical-biological model:
 Alzheimer’s Disease
 Alzheimer’s Dementia
Dubois criteriaDubois criteria
MCI or episodic memory debts for more than 6 months
+
CSF (P-tau o βA42)
or
MRI (entorhinal atrophy/amygdala)
or
PET (bilateral temporal hypometabolism or PET-PIB)
or
ApoE (4-4)

11. Toward to a pre-symptomatic diagnosis ofToward to a pre-symptomatic diagnosis of
Alzheimer’sAlzheimer’s
Marcos Díaz Diaz
Salamanca 2013